Press Releases
  Date Title View
ROCKVILLE, Md., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Food and Drug Administration (FDA) has granted tentative approval to the Company's Supp...
Posted: Aug 19, 2016
ROCKVILLE, Md., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Dr. M. James Barrett, Ph.D., has resigned from its Board of Directors effective Augus...
Posted: Aug 12, 2016
Second quarter 2016 product prescriptions totaled 123,758, a 38.9% increase over the second quarter of 2015.Net product sales for second quarter 2016 were $50.3 million, a 46.9% increase over the second quarter of 2015.Operating income for second quarter 2016 was $10.4 million compared to $3.1 million in the second quarter of 2015.   Diluted earnin...
Posted: Aug 2, 2016
ROCKVILLE, Md., July 20, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report the financial results for the second quarter of 2016 after 5:...
Posted: Jul 20, 2016
ROCKVILLE, Md., June 22, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced  the issuance on June 21, 2016 of a seventh patent (number 9,370,525) by the United States Paten...
Posted: Jun 22, 2016
ROCKVILLE, Md., June 16, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that it remains in discussions with the FDA regarding its Supplemental New Drug Application, or ...
Posted: Jun 16, 2016
ROCKVILLE, Md., June 02, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on May 31, 2016 of a sixth patent (number 9,351,975) by the United States Patent an...
Posted: Jun 2, 2016
ROCKVILLE, Md., May 24, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an overview and update of the Company and host investo...
Posted: May 24, 2016
ROCKVILLE, Md., May 10, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that, pursuant to a confidential partial settlement agreement, it has dismissed two patent infrin...
Posted: May 10, 2016
First quarter 2016 product prescriptions totaled 114,773, representing a 49.7% increase over the first quarter of 2015.Net product sales for first quarter 2016 were $43.0 million, a 53.1% increase over the first quarter of 2015.Operating income for first quarter 2016 was $5.3 million, a 55.0% increase over the first quarter of 2015.   Diluted earni...
Posted: May 3, 2016
1
...
NextLast
= add release to Briefcase